TrialPloS one2013

Pharmacodynamic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis subjects: a randomized, double-blind phase 1/2 study.

Christian Wolf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.